| 6.21 1.87 (43.09%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.46 |
1-year : | 8.71 |
| Resists | First : | 6.38 |
Second : | 7.46 |
| Pivot price | 4.86 |
|||
| Supports | First : | 4.76 |
Second : | 3.75 |
| MAs | MA(5) : | 4.65 |
MA(20) : | 4.72 |
| MA(100) : | 3.99 |
MA(250) : | 3.13 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 49 |
D(3) : | 34.3 |
| RSI | RSI(14): 69.8 |
|||
| 52-week | High : | 6.38 | Low : | 1.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IOVA ] has closed above the upper band by 15.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 83.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.39 - 6.42 | 6.42 - 6.45 |
| Low: | 5.56 - 5.59 | 5.59 - 5.62 |
| Close: | 6.15 - 6.21 | 6.21 - 6.26 |
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Thu, 06 Aug 2026
Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highl - GuruFocus
Thu, 06 Aug 2026
Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next - Yahoo Finance
Thu, 06 Aug 2026
Iovance Biotherapeutics Q2 Earnings Call Highlights - Yahoo Finance
Thu, 06 Aug 2026
Earnings call transcript: Iovance beats Q2 2026 estimates, shares jump 30% - Investing.com
Thu, 06 Aug 2026
Iovance Biotherapeutics Releases Q2 2026 Financial Results - AlphaStreet
Thu, 06 Aug 2026
Iovance stock surges as Amtagvi powers Q2 beat (IOVA:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 447 (M) |
| Shares Float | 388 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 67.7 (%) |
| Shares Short | 99,890 (K) |
| Shares Short P.Month | 103,490 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | -124 % |
| Operating Margin | -113.5 % |
| Return on Assets (ttm) | -23.7 % |
| Return on Equity (ttm) | -47.6 % |
| Qtrly Rev. Growth | 44.7 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.63 |
| EBITDA (p.s.) | -0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -271 (M) |
| Levered Free Cash Flow | -149 (M) |
| PE Ratio | -6.75 |
| PEG Ratio | 0 |
| Price to Book value | 3.76 |
| Price to Sales | 9.7 |
| Price to Cash Flow | -10.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|